Neurogene Inc
NGNE
查看详细走势图
17.230USD
+0.860+5.25%
收盘 02/06, 16:00（美东）报价延迟15分钟
254.58M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+5.25%
5天
-2.43%
1月
-7.76%
6月
-18.80%
今年开始到现在
-16.36%
1年
-15.79%
查看详细走势图
TradingKey Neurogene Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Neurogene Inc当前公司基本面数据相对谨慎，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名73/392位。机构持股占比非常高，近一月多位分析师给出公司评级为强力买入。最高目标价59.00。中期看，股价处于下降通道。近一个月，市场表现一般，但技术面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Neurogene Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Neurogene Inc亮点
亮点风险
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.
业绩增长期
公司处于发展阶段，最新年度总收入925.00K美元
利润高增长
公司净利润处于行业前列，最新年度总收入925.00K美元
估值合理
公司最新PE估值-4.20，处于3年历史合理位
机构减仓
最新机构持股16.38M股，环比减少12.93%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值845.00
活跃度降低
近期活跃度降低，过去20天平均换手率-0.48
分析师目标
根据
6
位分析师
强力买入
评级
59.000
目标均价
+242.43%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Neurogene Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Neurogene Inc简介
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.
公司代码NGNE
公司Neurogene Inc
CEOMcMinn (Rachel L)
网址https://www.neurogene.com/
相关品种
